Varlilumab clinical trials
Also written CDX-1127.
- studies test it
- 13
- open now
- 0
- in phase 3
- 0
- first study started
- 2011
How each study uses varlilumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2015 (4)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2014 | 3 |
| 2015 | 4 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 6
Celldex Therapeutics (6) · National Cancer Institute (NCI) (2) · Annick Desjardins, MD (1) · University Hospital Southampton NHS Foundation Trust (1) · Cascadian Therapeutics Inc. (1) · Rutgers, The State University of New Jersey (1) · James Larner, MD (1)
Often tested with
Tested in the same studies.
Diphtheria-Tetanus Vaccine (1) · Cobimetinib (1) · Liposomal MUC1/PET-lipid A Vaccine ONT-10 (1) · Glembatumumab vedotin (1) · CDX-301 (1) · flt3 ligand protein (1) · Rasdegafusp alfa (1) · Poly ICLC (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test varlilumab.
- Mar 2027DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without VarlilumabPhase 2 · Annick Desjardins, MD
Studies
Open first, then newest update. How each study uses varlilumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 13
- Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell LymphomasActive, not recruitingPhase 2National Cancer Institute (NCI)NCT03038672Written as VarlilumabHow we know
- DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without VarlilumabActive, not recruitingPhase 2Annick Desjardins, MDNCT03688178Written as VarlilumabHow we know
- Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLCTerminatedPhase 1Rutgers, The State University of New JerseyNCT04081688Written as Varlilumab 3 mg/kgHow we know
- Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract CancerActive, not recruitingPhase 2National Cancer Institute (NCI)NCT04941287Written as VarlilumabHow we know
- A Combination of Rituximab and Varlilumab Immunotherapy in Patients with B-cell LymphomaCompletedPhase 1/2University Hospital Southampton NHS Foundation TrustNCT03307746Written as VarlilumabHow we know
- A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid TumorsCompletedPhase 1/2Celldex TherapeuticsNCT02335918Written as Combination of varlilumab and nivolumabHow we know
- A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced MelanomaTerminatedPhase 2Celldex TherapeuticsNCT02302339Written as glembatumumab vedotin and varlilumabHow we know
- A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell CarcinomaTerminatedPhase 1Celldex TherapeuticsNCT02386111Written as Combination of varlilumab and sunitinibHow we know
- Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast CancerCompletedPhase 1Cascadian Therapeutics Inc.NCT02270372Written as ONT-10, Varlilumab combinationHow we know
- Pilot Study of SBRT and CDX-1127 in Prostate CancerTerminatedPhase 1James Larner, MDNCT02284971Written as CDX1127How we know
- A Study of Varlilumab and Atezolizumab in Patients With Advanced CancerTerminatedPhase 1Celldex TherapeuticsNCT02543645Written as Combination of Varlilumab and AtezolizumabHow we know
- A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic CancersCompletedPhase 1Celldex TherapeuticsNCT01460134Written as CDX-1127How we know
- A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV MelanomaTerminatedPhase 1/2Celldex TherapeuticsNCT02413827Written as Combination of varlilumab and ipilimumabHow we know
Given beside what is tested · 2 — varlilumab is usual care or a partner of the new treatment
- A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)TerminatedPhase 1Nicholas ButowskiNCT02924038Written as VarlilumabHow we know
- Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV MelanomaCompletedPhase 1/2Craig L Slingluff, JrNCT03617328Written as CDX-1127How we know
Codes
What other systems call varlilumab · ClinicalTrials.gg INT000769
- MeSH (NLM) C000622120varlilumabOne source NLM
- UNII (FDA) 0125DUV5XCVARLILUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q21098904VarlilumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C99127VarlilumabOne source FDA
- DrugBank DB11930One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000622120 | varlilumab | One source NLM |
| UNII (FDA) | 0125DUV5XC | VARLILUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q21098904 | Varlilumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C99127 | Varlilumab | One source FDA |
| DrugBank | DB11930 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.